AML1-MTG8 generated by t(8;21) contributes to leukemic transformation, but additional events are required for full leukemogenesis. We examined whether mutations in the receptor tyrosine kinase (RTK) pathway could be the genetic events that cause acute myeloblastic leukemia (AML) harboring t(8;21). Mutations in the second tyrosine kinase domain, juxtamembrane (JM) domain and exon 8 of the C-KIT gene were observed in 10, one and three of 37 AML patients with t(8;21), respectively. Three patients showed an internal tandem duplication in the JM domain of the FLT3 gene. One patient had a mutation in the K-Ras gene at codon 12. As the occurrence of these mutations was mutually exclusive, a total of 18 (49%) patients showed mutations in the RTK pathway. These results suggest that activating mutations in the RTK pathway play a role in part as an additional event leading to the development of t(8;21) AML. The 6-year cumulative incidence of relapse in patients with RTK pathway mutations was 79.8%, compared with 13.5% in patients lacking such mutations (P ¼ 0.0029). Furthermore, the 6-year relapse-free survival in patients with mutations was 18% compared to 60% in those without mutations (P ¼ 0.0340), indicating that RTK mutations are associated with the clinical outcome in t(8;21) AML.
Introduction
Chromosomal abnormality identifies a distinct subgroup with predictable clinical features and therapeutic outcomes in acute myeloblastic leukemia (AML). 1 The Runt domain transcription factor AML1/RUNX1, which is essential for the generation of definitive hematopoietic stem cells, was initially identified as a gene in the breakpoint of t(8;21)(q22;q22). 2 The heterodimeric non-DNA-binding subunit PEBP2b/CBFb has also been demonstrated to be the target of inv(16)(p13q22) in AML with M4Eo morphology. Patients with AML harboring t(8;21) or inv (16) have been found to comprise a group with a relatively favorable outcome in regard to the complete remission (CR) rate, relapse risk and overall survival (OS) compared with other subtypes. 1 Although approximately 50% of patients with the favorable karyotype show long-term survival, the treatment outcome is not universally favorable in these patients. 1 In t(8:21) AML, a worse outcome has been reported in patients with a high presenting leukocyte count, expression of the neural cell adhesion molecule CD56, or extramedullary disease at diagnosis. [3] [4] [5] [6] However, most of these poor prognostic factors have not been well established to date. Furthermore, genetic alterations that are associated with the clinical outcome in patients with t(8;21) AML remain to be determined.
The t (8;21) generates the AML1-MTG8 (ETO) fusion protein that is thought to interfere with the normal activity of AML1/ PEBP2b in a dominant-negative manner and contributes to impaired differentiation of hematopoietic cells. 7, 8 However, studies using conditional transgenic and knock-in mice have revealed that AML1-MTG8 contributes to leukemic transformation and that additional genetic events are required for full leukemogenesis. 9, 10 Recently, mutations in the members of the class III receptor tyrosine kinase (RTK) subfamily including C-KIT and FLT3 were found in patients with t(8;21) AML. [11] [12] [13] [14] [15] In this study, we examined whether mutations in the C-KIT, FLT3, PDGFRa, N-Ras, K-Ras or PTPN11 genes could be the additional genetic events required for leukemogenesis in t(8;21) AML. We also analyzed the clinical significance of mutations in the RTK pathway among AML patients with t(8;21).
Materials and methods

Patients and cell preparation
A total of 37 patients with de novo AML harboring t(8;21)(q22;q22) were examined for the presence of mutations in the RTK pathway. Diagnoses of AML were made from the morphology and cytochemistry according to the FrenchAmerican-British (FAB) classification as well as immunophenotypic analysis.
16 AML1-MTG8 transcripts were confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR). 17 Informed consent to use the samples was obtained from each patient, according to guidelines based on the tenets of the revised Helsinki protocol by the Institutional Committees for the Protection of Human Subjects and Analysis of the Human Genome. Mononuclear cells were isolated from peripheral blood or bone marrow samples at the time of diagnosis and immediately immunophenotyped. 18 One patient aged 78 years with chronic obstructive lung disease received supportive therapy only. The remaining patients were treated with intensive chemotherapy consisting of anthracyclines and cytarabine based on the Japan Adult Leukemia Study Group protocols in the AML87, AML89, AML92 and AML95 studies. [19] [20] [21] The human mast cell leukemic cell line HMC-1 harboring two mutations, V560G and D816 V, in C-KIT served as a control. 22 
RT-PCR
Total cellular RNA was extracted from cryopreserved mononuclear cells by TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA). cDNA was synthesized using total RNA and oligo(dT) 12À18 primer with Superscript II reverse transcriptase (Invitrogen). The PCR was carried out in a DNA thermal cycler (Whatman Biometra, Goettingen, Germany) with Taq polymerase (Invitrogen) and primer sets for the amplification of C-KIT, FLT3, PDGFRa, N-Ras, K-Ras and PTPN11 (Supplementary Table 1 and Figure 1 ). After amplification of C-KIT exon 8, an aliquot of each reaction mixture was size-fractionated in an 8% polyacrylamide gel. 23 Nonisotopic RNase cleavage assays (NIRCA)
Mutations in the second tyrosine kinase (TK2) domain of the C-KIT gene (C-KIT-TK2) and N-Ras were screened by NIRCA using a Mutation Screener Kit (Ambion, Austin, TX, USA) as previously reported. 24 The second PCR products were converted to RNA by transcription with T7 polymerase. Each RNA sample was hybridized with the complementary transcript from the wild-type cDNA, cleaved with optimized RNase mixtures containing ethidium bromide, and electrophoresed in 2% agarose gels. Samples from four normal individuals as wildtype controls showed no cleavage either on their own or in cross-examinations with each other.
Screening of the internal tandem duplication (ITD) and D835 mutations in the FLT3 gene FLT3-ITD was examined by RT-PCR amplification of the juxtamembrane (JM) domain, followed by electrophoresis in an agarose gel, as previously reported. 13, 25 To detect mutations at D835, we used a restriction fragment length polymorphismmediated RT-PCR assay. 26 The amplified products were digested with EcoRV (NewEngland Biolabs, Beverly, MA, USA), and subjected to electrophoresis in an agarose gel.
DNA sequencing
Samples displaying abnormal NIRCA, agarose or polyacrylamide gel electrophoresis profiles compared to wild-type controls were directly sequenced after purification using microspin S-400HR columns (Amersham Biosciences, Buckinghamshire, UK). Mutations in the C-KIT-JM, PDGFRa, K-Ras and PTPN11 were primarily screened by direct sequencing. The PCR products were subjected to cycle sequencing (Applied Biosystems, Foster City, CA, USA). FLT3-ITD mutations were confirmed by sequencing after subcloning into the pGEM-T Easy vector (Promega Co., Madison, WI, USA).
Statistical analysis
Differences in patient characteristics were analyzed with the Mann-Whitney U test for continuous variables and the w 2 test or Fisher's exact test for binary variables. OS was calculated from the first day of therapy until death from any cause. Relapse-free survival (RFS) for patients who had achieved CR was determined as the duration from the date of the first CR to first relapse or death regardless of the cause. The probability of relapse was also estimated by the competing analysis of cumulative incidence of relapse (CIR). CIR was calculated from the date of CR to first relapse. For cumulative incidence analysis, death in CR was considered as a competing cause of failure. Estimation of survival distributions was performed using the Kaplan-Meier method and the differences were compared using the log-rank test. These statistical analyses were performed with StatView-J 5.0 (Abacus Concepts, Berkeley, CA, USA).
Results
Mutations in the C-KIT gene
All samples from 37 patients with t(8;21) AML showed expression of C-KIT mRNA, consistent with the immunophenotypic analysis, which revealed expression of the CD117 antigen on leukemia cells from all patients with t(8;21) AML.
18,27 By using NIRCA, seven (19%) patients had mutations in the TK2 domain of the C-KIT gene ( Figure 1a ). All of these seven mutations were further confirmed by sequencing and showed previously reported changes at codon D816 (Table 1) . 12 Another one patient (#12) showed cleaved bands in NIRCA ( Figure 1a ) and had a silent mutation at codon L862 (CTG-CTC), which corresponded to a previously reported polymorphism. 28 By using direct sequencing of the TK2 domain, we identified N822K mutations in another three patients, which were overlooked by NIRCA (Table 1 ). These TK2 mutations have been shown experimentally to generate constitutively active proteins. 22, 29 In the analysis of the JM domain, two patients showed additional sequences corresponding to previously described Table 1 . (b) C-KIT exon 8 transcripts were size-fractionated in an 8% polyacrylamide gel. Expression of the mutated allele is confirmed by the presence of heteroduplex bands (bracket) in addition to normal and/or inserted alleles (arrow). The lane numbers correspond to the patient numbers in Table 1 . Lane 15 represents a t(8;21) AML patient with the wild-type C-KIT exon 8. Lane M shows a 100 bp DNA ladder.
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T Nanri et al polymorphisms in exon 10 at codons 541 (ATG-CTG) and 550 (AAA-AAG). 23, 28 In addition, an insertion mutation in the JM domain of the C-KIT gene was identified in one patient (#11). This mutation consisted of a 6 bp in-frame insertion in exon 11 at codon 572 ( Table 1) .
The polyacrylamide gel electrophoresis of the exon 8 RT-PCR products showed abnormal profiles in three (8%) patients (Figure 1b) . The data from direct sequencing of exon 8 in all 37 patients were consistent with the profiles in the polyacrylamide gel electrophoresis. One patient (#12) showed a 6 bp insertion at codon D419, while two other patients (#13 and #14) had in-frame deletion plus insertion mutations, which involved the loss or replacement of codon D419 (Table 1) .
Mutations in the FLT3, PDGFRa, PTPN11, N-Ras and K-Ras genes Three patients showed an ITD in the JM domain of the FLT3 gene. All the FLT3-ITD mutations consisted of an in-frame insertion representing a tandem repeat of the preceding nucleotides with an insertion (Table 1) . No patients had a mutation at D835 of the FLT3 gene. By RT-PCR and direct sequencing, we found no mutations in the JM and TK2 domains of the PDGFRa gene or the N-terminal region of the PTPN11 gene in patients with t(8;21) AML. Seven patients showed a silent mutation at codon A603 (GCG-GCA) in the JM domain of the PDGFRa gene, which seemed to be a polymorphism. One patient (#18) had a mutation in codon 12 of the K-Ras gene, G12D. As the occurrence of these mutations in the C-KIT, FLT3 and K-Ras was mutually exclusive, a total of 18 (49%) patients had mutations in the RTK pathway (Table 1) .
Clinical characteristics of t(8;21) AML patients with RTK mutations
The clinical characteristics of the patients with t(8;21) AML are summarized in Table 2 . There were no significant differences in age, sex, hemoglobin, platelet counts, leukocyte counts, Table 1 Mutations in the RTK pathway genes in patients with t(8;21) AML
Parentheses indicate a previously described polymorphism.
b
The internal tandem duplication is indicated by the location of duplication plus number of the inserted nucleotides. 
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positivities of CD19 and CD56 antigens, or additional chromosomal abnormalities between the patients with and without RTK pathway mutations. Patients with RTK mutations had higher circulating blasts (P ¼ 0.0391), marrow blast percentages (P ¼ 0.0065) and serum LDH levels (P ¼ 0.0003) than those lacking mutations (Table 2) . Patient #11 showed trisomy 4 in addition to t(8;21) and loss of chromosome X, and had an insertion mutation in the JM domain of the C-KIT gene, which is mapped to chromosome 4. Interestingly, trisomy 4 in patients with t(8;21) AML is associated with mutations in the TK2 domain of the C-KIT gene. 12 None of the patients showed any abnormalities in chromosome 13 on which FLT3 is located.
Association of RTK mutations with the clinical outcome
We also analyzed the correlation between the clinical response to chemotherapy and RTK pathway mutations in t(8;21) AML. All 18 patients with RTK mutations achieved CR, whereas 16 of 18 (89%) patients lacking mutations obtained CR (P ¼ 0.4857).
The actual RFS at 6 years for the entire study population was 38%. The 6-year RFS in patients with and without RTK mutations were 18 and 60%, respectively (P ¼ 0.0340) (Figure 2a ). However, there was no significant correlation between RTK mutations and OS (P ¼ 0.7783) (Figure 2b ). Among the patients without mutations, four died due to infection during postremission chemotherapy or after allogeneic hematopoietic stem cell transplantation (HSCT), and one died of another cause after long-term remission. It should be noted that the 6-year CIR in patients with AML harboring RTK mutations was 79.8%, compared with 13.5% in patients lacking mutations (P ¼ 0.0029). Three patients with mutations received allogeneic HSCT after relapse and have achieved a continuous second CR. Two patients in each group also received allogeneic HSCT at the first CR. As a consequence, five of seven patients with AML harboring RTK mutations who continued CR received allogeneic HSCT. When patients who underwent HSCT were censored at the date of the HSCT, patients with mutations had a 6-year RFS of 10 vs 60% for the patients without mutations (P ¼ 0.0176).
Discussion
Our analysis of a group of t(8;21) AML patients demonstrated that approximately 50% of the patients harbored a mutation in either the RTK or Ras signal transduction pathways. This observation lends support to the two-hit model for the pathogenesis of AML proposed by Gilliland et al. 11 Activating mutations in the RTK pathway probably confer a proliferative and survival benefit to leukemic clones since FLT3 and Ras mutations can be an additional event during the clonal evolution of AML. 30 On the other hand, AML1-MTG8 appears to be associated with an initial step of leukemogenesis in which disruption of AML1 leads to a block of hematopoietic cell differentiation. 7, 8 Detection of loss-of-function mutations in the AML1 gene in sporadic AML and familial platelet disorder with predisposition to AML supports and extends the hypothesis that a decrease in AML1 activity may provide a common underlying mechanism for driving the initial step of pathogenesis in AML1-associated leukemias. 7, 24, 31 Valk et al 32 showed that 69% of patients with inv(16) AML possessed either a Ras or RTK mutation. In addition, a high prevalence of FLT3 mutations was also observed in AML M0 patients with an AML1 mutation. 25 Taken together, these observations suggest that activating mutations in the RTK pathway play an important role as an additional event leading to the development of AML1-associated leukemias. Alternatively, other unknown secondary genetic abnormalities might play a role in disease pathogenesis in patients with t(8;21) AML lacking an RTK mutation.
Although there are only a few studies involving large numbers of patients with AML, mutations in the C-KIT gene were observed in less than 5% of overall AML cases. 33, 34 We found missense mutations in the activation loop of C-KIT in 10 of 37 (27%) patients with t(8;21) AML, which was within the same range as previously observed frequencies for t(8;21) and apparently higher than the incidence in overall AML cases. 12, 34 In addition, three patients showed in-frame deletion and insertion mutations in exon 8, which involved codon D419 as reported by Gari et al. 23 Exon 8 of the C-KIT gene encodes the fifth immunoglobulin-like extracellular domain that appears to play a role in proteolytic cleavage of the receptor and is required for structural integrity of the cell surface receptor to permit normal binding of the ligand. 35 Care et al 34 found that exon 8 mutations are highly associated with inv(16) AML and a significant factor that adversely affects the relapse rate, suggesting that these mutations act as activating mutations. Kohl et al 36 reported that C-KIT exon 8 mutations caused hyperactivation of the receptor in response to stem cell factor 
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T Nanri et al and conferred IL-3 independent growth to murine Ba/F3 cells. We also identified an in-frame insertion mutation in the JM domain of the C-KIT gene in one patient. To date, this is the first reported case of AML with an in-frame insertion mutation in the JM domain. Since this insertion mutation occurred near the most common mutations seen in gastrointestinal stromal tumors, it is likely to be a gain-of-function mutation. 37 Constitutive activation of FLT3 by either ITDs in the JM region or substitution mutations in the activation loop has been demonstrated in approximately one third of patients with AML. 13, 14 We found FLT3-ITD mutations in three patients with t(8;21) AML, while no patients had the FLT3-D835 mutation. These FLT3-ITD mutations have been shown experimentally to generate constitutively active proteins. 11, 14, 38 Ras is one of the downstream effectors in the RTK pathway and its activating mutations have been found in up to 20% of AML patients. 13 Although the Ras mutations do not appear to be associated with any FAB subtype, t(8;21) AML showed a low prevalence of Ras mutations. 13 In line with this observation, we found a K-Ras mutation in only one patient with t(8;21). Although t(8;21) and inv (16) are rarely associated with FLT3 mutations, 13, 14, 39 ours and other studies disclosed a significant predominance of C-KIT mutations in these peculiar subtypes of AML. 12, 15, 32, 34 In t(8;21) AML, expression of C-KIT is definitely observed and the cell growth is stimulated in response to C-KIT ligand. 18, 27, 29 However, the mechanism that this subtype may predispose to acquire activating mutations in the selective RTK like C-KIT is to be examined.
We examined the clinical significance of the C-KIT, FLT3 and K-Ras mutations as a collective group to evaluate the role of RTK mutations in t(8;21) AML according to Meshinchi et al. 33 As this approach would not be appropriate for implementation in the clinical setting, the clinical significance of each mutation must be established individually before combining these mutations into a single group. However, the signal generated by activated FLT3 or C-KIT is transduced via the MAP, PI3 kinase and STAT pathways. 11, 38 In addition, although activating mutations in the RTK/Ras pathway were detected in nearly half of the t(8;21) AML cases, intriguingly, no patient harbored more than one mutation. This implies that an activating mutation may not confer a biological advantage to the redundancy of another activating mutation in the same pathway. Patients with an activating mutation in the RTK/Ras pathway as a collective group had significantly higher presenting marrow and circulating blast percentages and serum LDH levels than those without a mutation. This is consistent with the general consensus that the serum LDH level reflects the tumor burden of the leukemia and/ or a poor clinical outcome.
In this study, we demonstrated for the first time that the RTK mutations seen in patients with t(8;21) AML are significantly associated with a high CIR rate and poor RFS rate. FLT3-ITD mutations have been clearly associated with an increased relapse rate in several studies. 13, 14 However, the clinical significances of other RTK mutations in AML have not been individually established. In particular, the influences of the described C-KIT mutations in terms of prognosis remain unclear at present. In addition, FLT3-D835 mutations do not confer poor clinical results. 14, 39 Our results require confirmation in large series of patients treated with an equivalent therapy. Nonetheless, our study highlights the importance of RTK mutations as a prognostic factor in t(8;21) AML, providing a framework for a stratified treatment approach for this subgroup. Pediatric patients with all subtypes of AML carrying an activating mutation in the RTK or Ras pathways as a collective group also had a worse OS than patients without mutations. 33 Our study also provides the clinical implication that patients with RTK mutations may benefit from allogeneic HSCT. Furthermore, these findings are of significant clinical import as activating mutations in the RTK pathway can be potential therapeutic targets for specific tyrosine kinase inhibitors and Ras pathway inhibitors in patients with t(8;21) AML harboring RTK mutations. 11, 15 
